Novartis withdraws EU imatinib PAH filing
This article was originally published in Scrip
Executive Summary
Novartis is withdrawing its centralized EU marketing application for approval of its targeted anticancer imatinib for the additional indication of pulmonary arterial hypertension (PAH).